Literature DB >> 29218998

VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Fatima Donia Mili1, Tenecia Allen2, Paula Weinstein Wadell1, W Craig Hooper1, Christine De Staercke1, Christopher J Bean1, Cathy Lally3, Harland Austin3, Nanette K Wenger2.   

Abstract

AIM: The study objectives were to investigate the association between selected CYP2C9 and VKORC1 single nucleotide polymorphisms with serious bleeding or thrombotic risk, and to estimate mean daily maintenance dose of warfarin and international normalized ratio measurements among Blacks receiving warfarin anticoagulation.
METHODS: We conducted a retrospective cohort study among 230 Black adults receiving warfarin for a minimum of three consecutive months with a confirmed date of first dosage.
RESULTS: A lower mean daily maintenance dosage of warfarin was required to maintain an international normalized ratio measurement within the therapeutic range among Blacks with the VKORC1-1639G>A variant alleles ([G/A vs G/G, p = 0.02], [A/A vs G/A, p = 0.008] and [A/A vs G/G, p = 0.001]).
CONCLUSION: Data indicated that VKORC1-1639A variant allele influenced warfarin daily maintenance dosage among our small, likely admixed Black patient population.

Entities:  

Keywords:  Blacks; CYP2C9; VKORC1; VKORC1-1639G>A warfarin; anticoagulation; pharmacogenetics; thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 29218998      PMCID: PMC6727961          DOI: 10.2217/fca-2017-0025

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  63 in total

Review 1.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Perlegen sciences, inc.

Authors:  Eric Peacock; Phyllis Whiteley
Journal:  Pharmacogenomics       Date:  2005-06       Impact factor: 2.533

3.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

4.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

5.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

6.  CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.

Authors:  Aurel C Allabi; Jean-Luc Gala; Yves Horsmans
Journal:  Pharmacogenet Genomics       Date:  2005-11       Impact factor: 2.089

7.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

8.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Authors:  Simone Rost; Andreas Fregin; Vytautas Ivaskevicius; Ernst Conzelmann; Konstanze Hörtnagel; Hans-Joachim Pelz; Knut Lappegard; Erhard Seifried; Inge Scharrer; Edward G D Tuddenham; Clemens R Müller; Tim M Strom; Johannes Oldenburg
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

9.  Identification of the gene for vitamin K epoxide reductase.

Authors:  Tao Li; Chun-Yun Chang; Da-Yun Jin; Pen-Jen Lin; Anastasia Khvorova; Darrel W Stafford
Journal:  Nature       Date:  2004-02-05       Impact factor: 49.962

10.  Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.

Authors:  Aurel C Allabi; Jean-Luc Gala; Jean-Pierre Desager; Michel Heusterspreute; Yves Horsmans
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

View more
  3 in total

1.  Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.

Authors:  Jubby Marcela Galvez; Carlos Martin Restrepo; Nora Constanza Contreras; Clara Alvarado; Carlos-Alberto Calderón-Ospina; Nidia Peña; Ricardo A Cifuentes; Daniela Duarte; Paul Laissue; Dora Janeth Fonseca
Journal:  Pharmgenomics Pers Med       Date:  2018-10-16

2.  Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin.

Authors:  Maria Mariana Barros Melo da Silveira; Leiliandry de Araújo Melo; Filipe Maia Ferreira Gomes; Leonardo José de Cupertino Barreto da Rocha Andrade; Isabela Paulino Serur; Isabelle Cecília de Vasconcellos Piscoya; Raposo Marina Gueiros; Kleyton Palmeira do Ó; Raul Emídio de Lima; Victor Arthur Eulálio Brasileiro; Luydson Richardson Silva Vasconcelos; Dário Celestino Sobral Filho
Journal:  Appl Clin Genet       Date:  2019-08-02

Review 3.  Oral Anticoagulant Therapy-When Art Meets Science.

Authors:  Patricia Lorena Cîmpan; Romeo Ioan Chira; Mihaela Mocan; Florin Petru Anton; Anca Daniela Farcaş
Journal:  J Clin Med       Date:  2019-10-21       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.